

# FluCov Influenza Activity Report #17

18 March 2024


## Take home: elevated but decreasing influenza activity in the Northern Hemisphere

- North America and Europe:** Although decreasing, influenza activity in the United States remains elevated with moderate to high activity in some states and a recent increase in the percentage of positive tests. In Europe, influenza activity is decreasing or stable at country level. Denmark, Italy, Spain and the UK report very low activity (<10% positivity), moderate activity (20-30% positivity) was reported in France (week 9) and Germany.
- Asia:** Influenza overall positivity rate remained stable in China in week 10/2024, compared to week 9, with low activity (10-20% positivity) in Northern China and moderate activity (20-30% positivity) in Southern China.
- Circulating virus:** Globally, all seasonal influenza viruses except B/Yamagata are circulating. While B/Victoria predominated in China and increased in the US and Canada, A(H1N1)pdm09 dominated circulation in Europe.
- Vaccine match:** US (CDC) reports that vaccine components are well-matched to circulating A(H1N1)pdm09, B/Victoria and A(H3) clades. The same is true for Europe (ECDC) with the exception that some A(H3) viruses (2a.3a.1 clade) are less well-matched (ERVISS).
- Influenza Viruses of Pandemic Potential:** Four unrelated cases of influenza A(H9N2) were reported in China, all children <12 years old (ECDC).
- COVID hospitalizations:** Continue to decrease in England, EU and the US, after a peak around the end of 2023.

## Positive Influenza tests (%)


**Note:** the positivity rate graph for france was last updated week 09/2024

— Season 2023/2024   
 — Season 2022/2023   
 — Season 2021/2022   
 — Average of pre-COVID-19 seasons (2014/2015 to 2018/2019) [Min; Max]



## Weekly COVID-19 hospital admissions

(England, EU/EEA, US – admissions/100,000)



Displayed data is the most recent reported; it is possible that there may be a delay in reporting. Most recent estimates subject to change (e.g. may decline) due to ongoing testing of specimen.

---

### Data sources & details

China: China CDC

US: FluView (Clinical Laboratories)

DK: WHO FluNET (non-sentinel)

All others: WHO FluNet (sentinel)

COVID: US (Department of Health and Human Services) EU (ERVISS), England (UKHSA)

Vaccine match: US (CDC), EU (ERVISS)

### A Nivel publication

FluCov team: Bronke Boudewijns, Susanne Heemskerk, Marco Del Riccio, Daan van Kooten, Saverio Caini, Caroline Schneeberger, John Paget.

FluCov Influenza Activity Report #17: 18 March 2024. Netherlands, Utrecht: Nivel, 2024

### Websites for more information

Project Website: <https://www.nivel.nl/en/fluconv>

FluCoV Dashboard: <https://www.nivel.nl/en/fluconv-dashboard>

### Funding

The Nivel FluCov project is funded by Sanofi

---